Cure8 research brief
Why This Matters
Children with IBD are at higher risk for C. difficile and practices for diagnosing and treating CDI in pediatric IBD vary widely. Standardized, pediatric-specific guidance could reduce uncertainty and improve care.
Who Should Pay Attention
Pediatric IBD clinicians; parents and caregivers of children with IBD; pediatric gastroenterology centers; researchers focused on pediatric CDI.
Study Snapshot
What To Know
This national survey summarizes current real-world practices across pediatric IBD centers in Italy and highlights inconsistent diagnostic approaches and treatment choices for CDI in children with IBD. It does not test treatments or provide outcomes data.
The findings show widespread use of multiple CDI tests and variation in first-line antibiotic selection; recurrent CDI is typically treated with oral vancomycin, and fidaxomicin, FMT, or bezlotoxumab are considered for multiple recurrences.
Management of immunosuppression during CDI varied, with many centers delaying or using a cautious approach to starting biologics in severe colitis with CDI. Implications are that pediatric-specific, evidence-based guidelines are needed to reduce variability and address gaps in diagnosis and management.
Keep In Mind
Results come from a 2025 nationwide survey of Italian pediatric IBD centers (27 centers). This is descriptive, self-reported data and does not contain trial outcomes or efficacy comparisons.
Source Details
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.